Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults with Type 1 Diabetes

被引：0
|
作者：
Handelsman, Yehuda
Giaccari, Andrea
Sawhney, Sangeeta
Banks, Phillip L.
Davies, Michael J.
Lapuerta, Pablo
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1100-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1100-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SOTAGLIFLOZIN AS ADJUNCT TO INSULIN IN PEOPLE WITH TYPE 1 DIABETES
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2019, 21 (01): : 200 - 201
  • [32] Sotagliflozin and Insulin Combination for Patients With Type 1 Diabetes
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (03) : 365 - 365
  • [33] Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study
    Akturk, Halis Kaan
    Dong, Fran
    Snell-Bergeon, Janet K.
    Karakus, Kagan Ege
    Shah, Viral N.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2025, 19 (02): : 292 - 296
  • [34] Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study
    Akturk, Halis Kaan
    Dong, Fran
    Snell-Bergeon, Janet K.
    Karakus, Kagan Ege
    Shah, Viral N.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [35] Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)
    Buse, John B.
    Garg, Satish K.
    Rosenstock, Julio
    Bailey, Timothy S.
    Banks, Phillip L.
    Bode, Bruce W.
    Danne, Thomas
    Kushner, Jake A.
    Lane, Wendy
    Lapuerta, Pablo
    Mcguire, Darren K.
    Peters, Anne L.
    Reed, John H.
    Sawhney, Sangeeta
    Strumph, Paul
    DIABETES, 2018, 67
  • [36] The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
    Zhou, Feifei
    Du, Nannan
    Zhou, Lulin
    Wang, Chenxi
    Ren, He
    Sun, Qiang
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [37] Post Hoc Analysis of SURPASS-1 to-5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
    De Block, Christophe
    Peleshok, Jennifer
    Wilding, John P. H.
    Kwan, Anita Y. M.
    Rasouli, Neda
    Maldonado, Juan M.
    Wysham, Carol
    Liu, Minzhi
    Aleppo, Grazia
    Benneyworth, Brian D.
    DIABETES THERAPY, 2025, 16 (01) : 43 - 71
  • [38] The inTandem 2 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes
    Cariou, B.
    Danne, T.
    Banks, P.
    Brandle, M.
    Brath, H.
    Franek, E.
    Kushner, J. A.
    Lapuerta, P.
    McGuire, D. K.
    Peters, A.
    Sangeeta, S.
    Strumph, P.
    DIABETOLOGIA, 2018, 61 : S58 - S58
  • [39] The inTandem1 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes
    Garg, S. K.
    Buse, J.
    Rosenstock, J.
    Bailey, T.
    Banks, P.
    Bode, B. W.
    Danne, T.
    Kushner, J. A.
    Lane, W. S.
    Lapuerta, P.
    McGuire, D. K.
    Peters, A.
    Reed, J.
    Sawhney, S.
    Strumph, P.
    DIABETOLOGIA, 2018, 61 : S294 - S295
  • [40] Risk factors for decline in renal function among young adults with type 1 diabetes
    Schwandt, Anke
    Bergis, Dominik
    Denkinger, Michael
    Gollisch, Katja S. C.
    Sandig, Dirk
    Stingl, Harald
    Zimny, Stefan
    Holl, Reinhard W.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (10) : 940 - 946
12345